Provided by Tiger Fintech (Singapore) Pte. Ltd.

Verve Therapeutics

5.28
-0.1200-2.22%
Post-market: 5.20-0.0800-1.52%18:20 EDT
Volume:853.57K
Turnover:4.51M
Market Cap:468.84M
PE:-2.25
High:5.47
Open:5.47
Low:5.19
Close:5.40
Loading ...

Verve Therapeutics: Q4 Earnings Snapshot

Associated Press Finance
·
27 Feb

BRIEF-Verve Therapeutics Q4 EPS USD -0.58

Reuters
·
27 Feb

Verve Therapeutics Q4 Collaboration Revenue USD 13.08 Million

THOMSON REUTERS
·
27 Feb

Verve Therapeutics Announces Pipeline Progress and Reports Fourth Quarter and Full Year 2024 Financial Results

GlobeNewswire
·
27 Feb

Promising Outlook for Verve Therapeutics: Buy Rating Backed by Innovative Treatments and Strategic Partnerships

TIPRANKS
·
21 Feb

Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire
·
04 Feb

Verve Therapeutics to Participate in the Guggenheim Securities SMID Cap Biotech Conference

GlobeNewswire
·
29 Jan

Verve Therapeutics (VERV) Moves 18.7% Higher: Will This Strength Last?

Zacks
·
23 Jan

Verve Therapeutics Inc: Initial Data for Heart-2 Phase 1B Clinical Trial of Verve-102 Targeting Pcsk9 Expected in Q2 of 2025

THOMSON REUTERS
·
13 Jan

Verve Therapeutics Inc: Well-Capitalized With Cash Runway Extending Into Mid-2027

THOMSON REUTERS
·
13 Jan

Press Release: Verve Therapeutics Announces Pipeline Progress and Anticipated 2025 Milestones

Dow Jones
·
13 Jan

Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire
·
04 Jan

Why Is Verve Therapeutics, Inc. (VERV) Among the Top CRISPR Stocks to Invest In?

Insider Monkey
·
31 Dec 2024

Verve Therapeutics Slides As Insider Purchases Lose Another US$65k

Simply Wall St.
·
17 Dec 2024

Stifel Nicolaus Sticks to Their Buy Rating for Verve Therapeutics (VERV)

TIPRANKS
·
11 Dec 2024

Verve Therapeutics has positive read from NewAmsterdam data, says Stifel

TIPRANKS
·
11 Dec 2024